Frontline Cabozantinib Approved in Europe for Advanced RCC

May 17, 2018 – The European Commission has approved cabozantinib for previously untreated patients with intermediate- or poor-risk advanced renal cell carcinoma (RCC), based on a meaningful improvement in progression-free survival (PFS) versus sunitinib in the CABOSUN trial, according to Ipsen, which codevelops the treatment with Exelixis. In the phase II study, first-line treatment with cabozantinib reduced the risk of progression or death by 52% compared with sunitinib for … (leggi tutto)